Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab for pediatric-type solid tumors presenting in adulthood
2016-003946-99Phase 2Terminated
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in Nonhematologic neoplasms and cancer, sponsored by Grupo Español de Tumores Huérfanos e Infrecuentes. Primary endpoint: Overall response rate. Started Mar 2017; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2016-003946-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003946-99.